(Reuters) – Here’s what you need to know about the coronavirus right now:
Moderna vaccine has positive Phase 1 results
Moderna Inc’s experimental vaccine for the novel coronavirus showed it was safe and provoked immune responses in all 45 healthy volunteers in an early-stage study, U.S. researchers reported.
Moderna’s shot, mRNA-1273, uses ribonucleic acid (RNA) – a chemical messenger that contains instructions for making proteins. When injected into people, the vaccine instructs cells to make proteins that mimic the outer surface of the coronavirus, which the body recognises as a foreign invader, and mounts an immune response against.
In June, Moderna said it selected the 100-microgram dose for its late-stage study to minimize adverse reactions. At that dose, Moderna said the company is on track to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, starting in 2021, from the company’s internal U.S.